Douglas Farman, MD
Pulmonary Disease · Macon, GANPI 1144310954
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 106 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,154, more than ten times the $15 reported in 2021. That places this record below the midpoint for pulmonary disease clinicians in GA, where the typical reported total is $3,789.
Across 106 payments — averaging $21.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$480
- Insmed, Inc.$353
- ANI Pharmaceuticals, Inc.$218
- Philips North America LLC$195
- Baxter Healthcare$168
- Verona Pharma, Inc.$135
- plus $702 from 12 others
What the payments were for
- Food & beverage$2,14995%
- Education$1025%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 19 | $480 |
| Insmed, Inc. | 18 | $353 |
| ANI Pharmaceuticals, Inc. | 11 | $218 |
| Philips North America LLC | 16 | $195 |
| Baxter Healthcare | 8 | $168 |
| Verona Pharma, Inc. | 10 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 3 | $90 |
| Sanofi-aventis U.S. LLC | 1 | $90 |
| Sanofi | 3 | $88 |
| Amgen | 3 | $74 |
| Paratek Pharmaceuticals, Inc. | 3 | $58 |
| AstraZeneca | 3 | $52 |
| Inspire Medical Systems, Inc. | 2 | $44 |
| Johnson & Johnson | 2 | $30 |
| Tactile Systems Technology Inc | 1 | $20 |
| Bayer | 1 | $18 |
| Gilead | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CUVITRU$125
- NUCALA$124
- AREXVY$123
- PURIFIED CORTROPHIN GEL$123
How this compares
$2,251 in reported general payments places this provider in the 35th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArikayceAmikacin Liposomal/Neb.Accessr | 14 | $213,183 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 241 | $212,072 |
| AdempasRiociguat | 12 | $162,687 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 120 | $89,927 |
| SymbicortBudesonide/Formoterol Fumarate | 60 | $21,582 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $16,564 |
| EliquisApixaban | 21 | $15,601 |
| Advair HfaFluticasone Propion/Salmeterol | 36 | $14,290 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $10,038 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 270 | $6,948 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 35 | $5,174 |
| Megestrol Acetate | 41 | $3,612 |
| Roflumilast | 34 | $2,673 |
| Azithromycin | 150 | $2,557 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $2,340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $480 | $238,674294 claims |
| Insmed, Inc.Arikayce | $353 | $213,18314 claims |
| BayerAdempas | $18 | $162,68712 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $52 | $111,509180 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Macon
- Gerald TarirahMacon$29K
- Charles CallenderMacon$20K
- John KingMacon$19K
- Lawrence McDermottSavannah$963K
- Vivek SambharaGainesville$417K
- Chad MillerAustell$382K
- Nehal BhattAthens$371K
- Maria MascoloRincon$358K
- Colin SwensonAtlanta$255K
- David MillerDecatur$206K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.